OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy

NCT02058017 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Lactic and metabolic acidosis of OPB-51602 is not tolerable

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: OPB-51602

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]
[object Object]